🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our study in JAMA found that most people eligible for #lungcancerscreening (LCS) are already getting screened for breast & colon cancers. LCS eligible adults ARE receptive to cancer screening. They are NOT “hard to reach,” they are “hardly reached.”

Our paper on how we're uniting the cancer research and care communities in Canada to accelerate precision oncology is out in Cancer Cell! Read it now 👇

Perioperative GLP-1 receptor agonist use in diabetic patients was linked to lower rates of readmission, wound dehiscence, and hematoma 🏥💉. No increase in infection or bleeding was observed, but more research is needed. Weill Cornell Medicine Surgery Columbia Surgery journals.lww.com/annalsofsurger…

How does the microbiome influence lung cancer & immunotherapy? Stephen V Liu, MD talks with Drs. Arielle Elkrief & Bertrand Routy on a new episode of #LungCancerConsidered about the latest research, what we still don’t know, and more! 🎧 Listen now: bit.ly/MI-NSCLC

Have you submitted your abstract for #ELIXR25 yet? Don’t miss the opportunity to present amongst cutting edge leaders in the space! Submit yours below 👇

Neoadjuvant Avelumab (PD-L1) + Docetaxel triplet in gastro esophageal adenocarcinoma- a highly effective regimen. It’s been a long 8 years since we launched this trial, good to finally see in print! cell.com/cell-reports-m…

Traditional biomarkers (PDL1 CPS/TPS, MMR) of response to ICI not very informative in this phase 2 trial - but integrating scRNAseq data with multiplex imaging identified M2 Macrophage density and proximity to cancer cells predictive of poor response. A target for future studies

🧪Promising results from a new clinical trial! Adding a PD-L1 inhibitor to chemo before surgery may improve outcomes for advanced gastroesophageal cancer. Led by Dr. Alcindor & Dr. Ferri 🔗 Read more: rimuhc.ca/en/-/immunothe…

Science today faces a profound crisis. In my new book, I draw upon personal experience to propose evidence-based, actionable solutions to pressing issues in research funding, publishing, incentives, and administration. Available on Amazon in hardcover, paperback, and Kindle

SUPE_R Trial: PET v CT follow-up for stage I-III NSCLC after definitive treatment: - 750pts, 22% recurred - more recurrences detected by PET (90%) v CT (77%; p=0.02) - no diff in time-to-recurrence (HR 1.12) or OS (HR 0.97) btwn grps OncoAlert #LCSM jto.org/article/S1556-…

✨  Honored to be nominated for a seat on the IASLC Board of Directors! It’s an exciting opportunity to help shape the future of  #LungCancer  research and care. I’d be truly grateful for your support and your vote. 🙏 iaslc.org/2025-board-dir…

Set your #ASCO25 alarm clock to Chicago time for Lung Cancer oral presentations on Mon June 2! Honoured to present late breaker 5yr overall survival w neoadj chemo-nivo, alongside colleagues including Jamie Chaft (NeoADAURA) & Charlie Rudin (tarlatamab in SCLC)! #lcsm

We will provide a 1 week extension to April 8th in case you'd like to submit an abstract to attend our #ELIXR25 conference!

🚨Extension alert🚨! You now have until May 8th to submit your abstract for the chance to present at this cutting edge conference! Be part of the conversation by submitting yours below.

I believe in her spirit, passion, and dedication to her work. Tina’s remarkable ability to communicate science with simplicity and her unique commitment to research truly stand out. Vote Tina for SICT Board of Directors! #ScienceLeadership #SICT #WomenInSTEM #ResearchExcellence

My strongest support for Dr. Tina Cascone MD PhD who has been nominated for the Society for Immunotherapy of Cancer board of directors election! She is a truly outstanding physician scientist, generous collaborator, leader in SITC and great human being! Please vote! sitcancer.org/membership/202…

“It’s critically important to be a surgeon scientist. You have to be well-trained. You can’t be a surgeon scientist out of thin air. You need a surgeon who wants to do it, who is excited and realizes it’s hard work.” - Alec Patterson WashU Medicine Division of Cardiothoracic Surgery #AATS2025

tomorrow at noon! Really excited about this great opportunity for discussion about what resectability means in this new era of #LungCancer treatment! Stellar faculty donington Brendon Stiles Linda Martin #AATS2025 #tssmn Register today: bit.ly/BioANSCLC

This is meaningful. Pts with tumors that are big to resect, or who are very frail, are often referred to #radonc who feel compelled to treat. It’s crucial to consider upfront systemic tx and revisit 3-4 months later to avoid delivering anything futile. #ESTRO25 Cecilia Pompili MD PhD FACS

Let’s make X fun again and start asking thought provoking questions such as “Did MSKCC really use a Radium Bomb to treat cancer?” The linked YouTube video tells more about this early history before chemotherapy was discovered.